文献速递哮喘

Tralokinumab 在重症哮喘中未显示减少口服糖皮质激素的效应

Tralokinumab did not demonstrate oral corticosteroid-sparing effects in severe asthma.
PubMed 文献 · Eur Respir J · 2019-01-31

这项为期40周、随机双盲试验评估 tralokinumab 对需维持口服糖皮质激素(OCS)治疗的重症未控制哮喘患者的 OCS 节约潜力,140例患者随机接受 tralokinumab 300 mg 或安慰剂每2周皮下注射。第40周时,tralokinumab 组与安慰剂组最终每日平均 OCS 剂量较基线的百分比降低无显著差异(37.62% 对 29.85%;p=0.271),所有次要终点亦无显著组间差异。总体而言,tralokinumab 在重症哮喘中未显示 OCS 节约效应。

要点

  • tralokinumab 300 mg 每2周皮下注射未显著减少重症哮喘患者 OCS 维持剂量。
  • 第40周 OCS 剂量降低百分比组间无显著差异(37.62% 对 29.85%;p=0.271)。
  • tralokinumab 组上呼吸道感染报告比例较高(35.7% 对 14.3%),但无肺炎报告。

核心结论

  • tralokinumab 在需维持 OCS 治疗的重症未控制哮喘患者中未显示 OCS 节约效应。

研究设计与样本

  • 为期40周、随机、双盲试验,评估 tralokinumab 在需维持 OCS 加吸入糖皮质激素/长效β2受体激动剂的重症未控制哮喘患者中的 OCS 节约潜力。
  • 共140例患者随机接受 tralokinumab 300 mg 或安慰剂(每组 n=70),每2周皮下注射一次。

主要发现

  • 第40周时,tralokinumab 组与安慰剂组最终每日平均 OCS 剂量较基线的百分比降低无显著差异(37.62% 对 29.85%;p=0.271)。
  • 所有次要终点均无显著组间差异。
  • tralokinumab 组与安慰剂组的不良事件和严重不良事件报告总体相似。
  • tralokinumab 组报告上呼吸道感染的患者比例较高(35.7% 对 14.3%),但无肺炎报告。

关键数值与推荐

  • 主要终点为第40周时维持哮喘控制条件下平均 OCS 剂量较基线的百分比变化。
  • 次要终点包括处方维持 OCS 剂量≤5 mg 的患者比例、处方维持 OCS 剂量降低≥50% 的患者比例及哮喘急性发作率。

临床怎么用

  • 对于需维持 OCS 的重症哮喘患者,不应基于本试验结果预期 tralokinumab 可减少 OCS 用量。
  • 使用 tralokinumab 时需关注上呼吸道感染报告比例较高的情况。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Long-term oral corticosteroid (OCS) use in patients with severe asthma is associated with significant adverse effects.This 40-week, randomised, double-blind trial evaluated the OCS-sparing potential of tralokinumab in patients with severe, uncontrolled asthma requiring maintenance OCS treatment plus inhaled corticosteroids/long-acting β2-agonists. Overall, 140 patients were randomised to tralokinumab 300 mg or placebo (n=70 in each group) administered subcutaneously every 2 weeks. The primary end-point was percentage change from baseline in average OCS dose at week 40, while maintaining asthma control. Secondary end-points included proportion of patients with a prescribed maintenance OCS dose of ≤5 mg, those with a ≥50% reduction in prescribed maintenance OCS dose and asthma exacerbation rate. Safety was also assessed.At week 40, the percentage reduction from baseline in the final daily average OCS dose was not significantly different between tralokinumab and placebo (37.62% versus 29.85%; p=0.271). There were no significant between-treatment differences for any secondary end-point. Overall, reporting of adverse events and serious adverse events were similar for the tralokinumab and placebo groups. Although a greater proportion of tralokinumab-treated patients reported upper respiratory tract infections (35.7% versus 14.3%), there were no reported cases of pneumonia.Overall, tralokinumab did not demonstrate an OCS-sparing effect in patients with severe asthma.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Busse WW, Brusselle GG, Korn S, et al. Tralokinumab did not demonstrate oral corticosteroid-sparing effects in severe asthma. Eur Respir J. 2019. PMID: 30442714. doi:10.1183/13993003.00948-2018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。